Niki BioSolutions Regains Nasdaq Minimum $1.00 Bid Price Compliance

What Happened
Niki BioSolutions, Inc. (formerly Aptorum Group Limited) reported in an 8-K filed August 7, 2026 that Nasdaq has confirmed the company regained compliance with the minimum $1.00 per share bid-price requirement. Nasdaq notified the company that the closing bid price was at $1.00 or greater for 10 consecutive business days from July 21, 2026 through August 3, 2026, and on August 4, 2026 Nasdaq advised that the company had achieved compliance under Nasdaq Listing Rule 5550(a)(2). This follows a deficiency notice the company received on March 5, 2026.

Key Details

• Deficiency notice received March 5, 2026 for 30 consecutive business days below the $1.00 minimum bid price.
• Company was given a 180-calendar-day compliance period ending September 1, 2026.
• Stock closed at $1.00+ for 10 consecutive business days from July 21, 2026 to August 3, 2026.
• Nasdaq confirmed compliance by letter dated August 4, 2026 and the matter is now closed.

Why It Matters
Regaining compliance prevents potential delisting proceedings and allows Niki BioSolutions to remain listed on the Nasdaq Capital Market, preserving visibility and access to public markets for shareholders. This action addresses a technical listing requirement tied to the company’s share price; it does not by itself reflect the company’s financial results or operations. Investors should note compliance can be lost again if the stock price falls below the required threshold and monitor future announcements for any further listing developments.